Skip to main content area

UKMi Q&A via SPS – New Resources

UKMi publish a series of Q&A documents on the NHS SPS website, with summaries of high quality, evidence-based, and quality controlled answers to common or unusual Medicines Information enquiries.

The latest batch of seven new or updated Q&As was published in December:

Which medicines require extra care when switching between liquid and tablet/capsule formulations? Information on medicines which require dose adjustment when switching between different oral formulations, with advice on monitoring & a dose adjustment summary table.
NOACs and Antidepressants – What are the risks of using these together and how should these risks be managed? Considers the risk of interactions between NOACs and antidepressants.
Which opioids can be used in renal impairment? Renal impairment  affects clearance of opioids and active metabolites. Elimination may be prolonged. Caution is required. Doses should be reduced & some opioids should be avoided. Resource includes a dose recommendation table.
What is the first choice antidepressant for patients with renal impairment? Evaluates limited published evidence on the use of antidepressants in patients with renal impairment.
Statins – What is the evidence for their use in patients with renal impairment? Evaluates the evidence for use of statins in renal impairment and discusses current guidance.
What information is available on drugs in diving? Summary of information on drugs and medical conditions that may affect a person’s ability to dive.
What is the risk of interaction between opioids and monoamine oxidase inhibitors (MAOIs)? Combining MAOIs with some opioid analgesics may be associated with a risk of serotonin syndrome or opioid toxicity. Q&A reviews sources & provides advice on the cautious approach that might be taken with selected opioids.